GOLM1 and gastric cancer: In conclusion, our results suggest that GP73 correlates with the effect of neoadjuvant chemotherapy in gastric cancer and may serve as a promising biomarker to identify patients with poor prognosis, however, its potential role in the management of patients with gastric cancer needs to be further studied.